A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
Heart disease is more common in people over 65, but treatments are better than ever. That can complicate decision-making for ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback